{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:02:08Z","timestamp":1781200928596,"version":"3.54.1"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Comit\u00e9 des IVIg des Hospices Civils de Lyon","award":["2017"],"award-info":[{"award-number":["2017"]}]},{"name":"Agence Nationale Pour la Recherche","award":["ANR-16-CE17-0007-01"],"award-info":[{"award-number":["ANR-16-CE17-0007-01"]}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["PME20180639518"],"award-info":[{"award-number":["PME20180639518"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010481","name":"Etablissement Fran\u00e7ais du Sang","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,23]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The standard-of-care protocol, based on plasma exchanges, high-dose intravenous immunoglobulin and optimization of maintenance immunosuppression, can slow down the evolution of antibody-mediated rejection (AMR), but with high interindividual variability. Identification of a reliable predictive tool of the response to AMR treatment is a mandatory step for personalization of the follow-up strategy and to guide second-line therapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Interrogation of the electronic databases of 2 French university hospitals (Lyon and Strasbourg) retrospectively identified 81 renal transplant recipients diagnosed with AMR without chronic lesions (cg score\u00a0\u22641) at diagnosis and for whom a follow-up biopsy had been performed 3\u20136 months after initiation of therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The evolution of humoral lesions on follow-up biopsy (disappearance versus persistence versus progression) correlated with the risk for allograft loss (logrank test, P\u00a0=\u00a0.001). Patients with disappearance of humoral lesions had \u223c80% graft survival at 10 years. The hazard ratio for graft loss in multivariate analysis was 3.91 (P\u00a0=\u00a0.04) and 5.15 (P\u00a0=\u00a0.02) for patients with persistence and progression of lesions, respectively. The non-invasive parameters classically used to follow the intensity of humoral alloimmune response (evolution of immunodominant DSA mean fluorescence intensity) and the decline of renal graft function (estimated glomerular filtration rate decrease and persistent proteinuria) showed little clinical value to predict the histological response to AMR therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We conclude that invasive monitoring of the evolution of humoral lesions by the mean of follow-up biopsy performed 3\u20136 months after the initiation of therapy is an interesting tool to predict long-term outcome after AMR treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfac192","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T17:22:44Z","timestamp":1654708964000},"page":"2555-2568","source":"Crossref","is-referenced-by-count":3,"title":["Evolution of humoral lesions on follow-up biopsy stratifies the risk for renal graft loss after antibody-mediated rejection treatment"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3844-8922","authenticated-orcid":false,"given":"Antonin","family":"Bouchet","sequence":"first","affiliation":[{"name":"Service de Transplantation, N\u00e9phrologie et Immunologie Clinique, H\u00f4pital Edouard Herriot, Hospices Civils de Lyon , Lyon , France"},{"name":"Unit\u00e9 de Formation et de Recherche de M\u00e9decine Lyon Est, Universit\u00e9 Claude-Bernard Lyon I , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brieuc","family":"Muller","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation, Les H\u00f4pitaux Universitaires de Strasbourg , Strasbourg , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Olagne","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation, Les H\u00f4pitaux Universitaires de Strasbourg , Strasbourg , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Barba","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Formation et de Recherche de M\u00e9decine Lyon Est, Universit\u00e9 Claude-Bernard Lyon I , Lyon , France"},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale U1111 , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Joly","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation, Les H\u00f4pitaux Universitaires de Strasbourg , Strasbourg , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustin","family":"Obrecht","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation, Les H\u00f4pitaux Universitaires de Strasbourg , Strasbourg , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Rabeyrin","sequence":"additional","affiliation":[{"name":"Institut de Pathologie Multisite, Groupement Hospitalier Est , Bron , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Dijoud","sequence":"additional","affiliation":[{"name":"Institut de Pathologie Multisite, Groupement Hospitalier Est , Bron , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-4531","authenticated-orcid":false,"given":"C\u00e9cile","family":"Picard","sequence":"additional","affiliation":[{"name":"Institut de Pathologie Multisite, Groupement Hospitalier Est , Bron , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mezaache","sequence":"additional","affiliation":[{"name":"Service de Transplantation, N\u00e9phrologie et Immunologie Clinique, H\u00f4pital Edouard Herriot, Hospices Civils de Lyon , Lyon , France"},{"name":"Unit\u00e9 de Formation et de Recherche de M\u00e9decine Lyon Est, Universit\u00e9 Claude-Bernard Lyon I , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Sicard","sequence":"additional","affiliation":[{"name":"Service de Transplantation, N\u00e9phrologie et Immunologie Clinique, H\u00f4pital Edouard Herriot, Hospices Civils de Lyon , Lyon , France"},{"name":"Unit\u00e9 de Formation et de Recherche de M\u00e9decine Lyon Est, Universit\u00e9 Claude-Bernard Lyon I , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Koenig","sequence":"additional","affiliation":[{"name":"Service de Transplantation, N\u00e9phrologie et Immunologie Clinique, H\u00f4pital Edouard Herriot, Hospices Civils de Lyon , Lyon , France"},{"name":"Unit\u00e9 de Formation et de Recherche de M\u00e9decine Lyon Est, Universit\u00e9 Claude-Bernard Lyon I , Lyon , France"},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale U1111 , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Parissiadis","sequence":"additional","affiliation":[{"name":"Laboratoire d'Histocompatibilit\u00e9, Etablissement Fran\u00e7ais du Sang , Strasbourg , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Dubois","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale U1111 , Lyon , France"},{"name":"Laboratoire d'Histocompatibilit\u00e9, Etablissement Fran\u00e7ais du Sang , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Morelon","sequence":"additional","affiliation":[{"name":"Service de Transplantation, N\u00e9phrologie et Immunologie Clinique, H\u00f4pital Edouard Herriot, Hospices Civils de Lyon , Lyon , France"},{"name":"Unit\u00e9 de Formation et de Recherche de M\u00e9decine Lyon Est, Universit\u00e9 Claude-Bernard Lyon I , Lyon , France"},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale U1111 , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Caillard","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie et Transplantation, Les H\u00f4pitaux Universitaires de Strasbourg , Strasbourg , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Thaunat","sequence":"additional","affiliation":[{"name":"Service de Transplantation, N\u00e9phrologie et Immunologie Clinique, H\u00f4pital Edouard Herriot, Hospices Civils de Lyon , Lyon , France"},{"name":"Unit\u00e9 de Formation et de Recherche de M\u00e9decine Lyon Est, Universit\u00e9 Claude-Bernard Lyon I , Lyon , France"},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale U1111 , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"key":"2022112304500784500_bib1","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant","volume":"341","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"2022112304500784500_bib2","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1111\/j.1600-6143.2011.03686.x","article-title":"Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes","volume":"11","author":"Tonelli","year":"2011","journal-title":"Am J Transplant"},{"key":"2022112304500784500_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.1996.307","article-title":"A study of the quality of life and cost-utility of renal transplantation","volume":"50","author":"Laupacis","year":"1996","journal-title":"Kidney Int"},{"key":"2022112304500784500_bib4","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1681\/ASN.2014060588","article-title":"Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients","volume":"26","author":"Halloran","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2022112304500784500_bib5","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1681\/ASN.2015070781","article-title":"Effect of immunosuppressive drugs on humoral allosensitization after kidney transplant","volume":"27","author":"Thaunat","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2022112304500784500_bib6","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.3389\/fimmu.2018.03178","article-title":"Residual activatability of circulating Tfh17 predicts humoral response to thymodependent antigens in patients on therapeutic immunosuppression","volume":"9","author":"Dahdal","year":"2018","journal-title":"Front Immunol"},{"key":"2022112304500784500_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fimmu.2018.00275","article-title":"CD4+ T cell help is mandatory for naive and memory donor-specific antibody responses: impact of therapeutic immunosuppression","volume":"9","author":"Chen","year":"2018","journal-title":"Front Immunol"},{"key":"2022112304500784500_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/TP.0000000000000958","article-title":"One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial","volume":"100","author":"Sautenet","year":"2016","journal-title":"Transplantation"},{"key":"2022112304500784500_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2022112304500784500_bib10","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1681\/ASN.2018121254","article-title":"Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use","volume":"30","author":"Kwun","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2022112304500784500_bib11","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1097\/TP.0000000000001069","article-title":"B cells and antibodies in transplantation","volume":"100","author":"Koenig","year":"2016","journal-title":"Transplantation"},{"key":"2022112304500784500_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am J Transplant"},{"key":"2022112304500784500_bib13","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1111\/j.1600-6143.2009.02799.x","article-title":"Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure","volume":"9","author":"Einecke","year":"2009","journal-title":"Am J Transplant"},{"key":"2022112304500784500_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.trim.2011.11.003","article-title":"Humoral immunity in chronic allograft rejection: puzzle pieces come together","volume":"26","author":"Thaunat","year":"2012","journal-title":"Transpl Immunol"},{"key":"2022112304500784500_bib15","doi-asserted-by":"crossref","article-title":"Recent advances in renal transplantation: antibody-mediated rejection takes center stage","author":"Pouliquen","DOI":"10.12703\/P7-51"},{"key":"2022112304500784500_bib16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"Kidney Disease: Improving Global Outcomes Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"2022112304500784500_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ajt.12589","article-title":"Diagnosis and management of antibody-mediated rejection: current status and novel approaches","volume":"14","author":"Djamali","year":"2014","journal-title":"Am J Transplant"},{"key":"2022112304500784500_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-6143.2006.01613.x","article-title":"Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial","volume":"7","author":"B\u00f6hmig","year":"2007","journal-title":"Am J Transplant"},{"key":"2022112304500784500_bib19","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1600-6143.2009.02591.x","article-title":"Comparison of combination plasmapheresis\/IVIg\/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection","volume":"9","author":"Lefaucheur","year":"2009","journal-title":"Am J Transplant"},{"key":"2022112304500784500_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1681\/ASN.2013101144","article-title":"Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss","volume":"26","author":"Sicard","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2022112304500784500_bib21","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/1744-9987.12430","article-title":"Treatment of antibody-mediated rejection after kidney transplantation","volume":"20","author":"Gubensek","year":"2016","journal-title":"Ther Apher Dial"},{"key":"2022112304500784500_bib22","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2022112304500784500_bib23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/ajt.14015","article-title":"Evaluation of C1q status and titer of de novo donor-specific antibodies as predictors of allograft survival","volume":"17","author":"Wiebe","year":"2017","journal-title":"Am J Transplant"},{"key":"2022112304500784500_bib24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.transproceed.2013.02.106","article-title":"Increase in proteinuria after acute kidney graft rejection is associated with decreased graft function and survival","volume":"45","author":"Oblak","year":"2013","journal-title":"Transplant Proc"},{"key":"2022112304500784500_bib25","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1600-6143.2009.02577.x","article-title":"Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss","volume":"9","author":"Everly","year":"2009","journal-title":"Am J Transplant"},{"key":"2022112304500784500_bib26","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1681\/ASN.2017070749","article-title":"Dynamic prognostic score to predict kidney allograft survival in patients with antibody-mediated rejection","volume":"29","author":"Viglietti","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2022112304500784500_bib27","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/nm.3313","article-title":"AKT2 is essential to maintain podocyte viability and function during chronic kidney disease","volume":"19","author":"Canaud","year":"2013","journal-title":"Nat Med"},{"key":"2022112304500784500_bib28","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2004070549","article-title":"Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function","volume":"16","author":"Froissart","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2022112304500784500_bib29","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant"},{"key":"2022112304500784500_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1751-0473-3-17","article-title":"Purposeful selection of variables in logistic regression","volume":"3","author":"Bursac","year":"2008","journal-title":"Source Code Biol Med"},{"key":"2022112304500784500_bib31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/tri.12895","article-title":"Five myths about variable selection","volume":"30","author":"Heinze","year":"2017","journal-title":"Transpl Int"},{"key":"2022112304500784500_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41512-020-00074-3","article-title":"State of the art in selection of variables and functional forms in multivariable analysis-outstanding issues","volume":"4","author":"Sauerbrei","year":"2020","journal-title":"Diagn Progn Res"},{"key":"2022112304500784500_bib33","first-page":"1","article-title":"RAWGraphs: a visualisation platform to create open outputs","author":"Mauri","year":"2017","journal-title":"Proceedings of the 12th Biannual Conference on Italian SIGCHI Chapter"},{"key":"2022112304500784500_bib34","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/ajt.13347","article-title":"Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody","volume":"15","author":"Wiebe","year":"2015","journal-title":"Am J Transplant"},{"key":"2022112304500784500_bib35","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.kint.2016.10.040","article-title":"Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent\/recurrent versus de novo donor-specific antibodies","volume":"91","author":"Haas","year":"2017","journal-title":"Kidney Int"},{"key":"2022112304500784500_bib36","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1681\/ASN.2016070797","article-title":"Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients","volume":"28","author":"Aubert","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2022112304500784500_bib37","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/01.TP.0000442503.85766.91","article-title":"Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies","volume":"97","author":"Gupta","year":"2014","journal-title":"Transplantation"},{"key":"2022112304500784500_bib38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/01.tp.0000282870.71282.ed","article-title":"To biopsy or not to biopsy? Should we screen the histology of stable renal grafts?","volume":"84","author":"Thaunat","year":"2007","journal-title":"Transplantation"},{"key":"2022112304500784500_bib39","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1097\/01.TP.0000121134.96928.0E","article-title":"Complications of protocol renal biopsy","volume":"77","author":"Fereira","year":"2004","journal-title":"Transplantation"},{"key":"2022112304500784500_bib40","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/01.TP.0000082542.99416.11","article-title":"Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates","volume":"76","author":"Furness","year":"2003","journal-title":"Transplantation"},{"key":"2022112304500784500_bib41","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/ajt.13663","article-title":"C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study","volume":"16","author":"Viglietti","year":"2016","journal-title":"Am J Transplant"},{"key":"2022112304500784500_bib42","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients","volume":"17","author":"Choi","year":"2017","journal-title":"Am J Transplant"},{"key":"2022112304500784500_bib43","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00007890-199902150-00016","article-title":"Histological outcome of acute cellular rejection in kidney transplantation after treatment with methylprednisolone","volume":"67","author":"Mazzucchi","year":"1999","journal-title":"Transplantation"},{"key":"2022112304500784500_bib44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/tri.13325","article-title":"Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss","volume":"32","author":"Cioni","year":"2019","journal-title":"Transpl Int"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfac192\/45241400\/gfac192.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/12\/2555\/47203090\/gfac192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/12\/2555\/47203090\/gfac192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T04:50:55Z","timestamp":1669179055000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/37\/12\/2555\/6604385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6,8]]},"published-print":{"date-parts":[[2022,11,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfac192","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12]]},"published":{"date-parts":[[2022,6,8]]}}}